AUTHOR=Tu Xiaoting , Ren Hongyan , Bu Shurui 

TITLE=Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters

JOURNAL=Frontiers in Microbiology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1274559

DOI=10.3389/fmicb.2023.1274559

ISSN=1664-302X

ABSTRACT=<sec><title>Introduction</title><p>Constipation-predominant irritable bowel syndrome (IBS-C) is a functional bowel disease that affects 10–20% of the population worldwide. Curcumin (CUR) is widely used in traditional Chinese medicine to treat IBS, but its mechanism of action needs further investigation.</p></sec><sec><title>Methods</title><p>In this study, we used mosapride (MOS) as a positive control to evaluate the changes in gut microbiota in IBS-C rat models after treatment with CUR or MOS by analyzing 16S rDNA variation. In addition, we used enzyme immunoassay kits and immunohistochemical analysis to investigate whether CUR or MOS influenced serotonin (5-HT), substance P (SP), and vasoactive intestinal peptide (VIP) levels in the serum and colon of IBS-C rats.</p></sec><sec><title>Results</title><p>The study showed that rats supplemented with CUR showed significantly increased fecal weight, fecal water content, small intestine transit rate and significantly decreased serum levels of 5-HT, VIP and SP compared to the IBS group (<italic>p</italic> &lt; 0.05). In addition, treatment with CUR changed the relative abundance of <italic>Blautia</italic>, <italic>Sutterella</italic>, <italic>Acetanaerobacterium</italic> and <italic>Ruminococcus</italic>2 in the gut microbiota.</p></sec><sec><title>Discussion</title><p>This study showed that the efficacy of CUR on IBS-C was possibly by modulating the microbiota and lowering the serum levels of HT, SP, and VIP.</p></sec>